Kisqali Femara Co-Pack (ribociclib/letrozole) — United Healthcare
Advanced, recurrent, or metastatic breast cancer
Initial criteria
- Diagnosis of advanced, recurrent, or metastatic breast cancer
- AND Disease is hormone receptor (HR)-positive
- AND Disease is human epidermal growth factor receptor 2 (HER2)-negative
Reauthorization criteria
- Patient does not show evidence of progressive disease while on Kisqali Femara Co-Pack therapy
Approval duration
12 months